



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Wang, CYT;Ballard, EL;Pava, Z;Marquart, L;Gaydon, J;Murphy, SC;Whiley, D;O'Rourke, P;McCarthy, JS

Title:

Analytical validation of a real-time hydrolysis probe PCR assay for quantifying Plasmodium falciparum parasites in experimentally infected human adults

Date:

2021-12-01

Citation:

Wang, C. Y. T., Ballard, E. L., Pava, Z., Marquart, L., Gaydon, J., Murphy, S. C., Whiley, D., O'Rourke, P. & McCarthy, J. S. (2021). Analytical validation of a real-time hydrolysis probe PCR assay for quantifying Plasmodium falciparum parasites in experimentally infected human adults. *Malaria Journal*, 20 (1), <https://doi.org/10.1186/s12936-021-03717-y>.

Persistent Link:

<https://hdl.handle.net/11343/278024>

License:


CC BY

RESEARCH

Open Access



Analytical validation of a real-time hydrolysis probe PCR assay for quantifying *Plasmodium falciparum* parasites in experimentally infected human adults

Claire Y. T. Wang^{1,2*} , Emma L. Ballard³, Zuleima Pava³, Louise Marquart³, Jane Gaydon^{1,2}, Sean C. Murphy^{4,5}, David Whiley^{1,6}, Peter O'Rourke³ and James S. McCarthy^{3,7}

Abstract

Background: Volunteer infection studies have become a standard model for evaluating drug efficacy against *Plasmodium* infections. Molecular techniques such as qPCR are used in these studies due to their ability to provide robust and accurate estimates of parasitaemia at increased sensitivity compared to microscopy. The validity and reliability of assays need to be ensured when used to evaluate the efficacy of candidate drugs in clinical trials.

Methods: A previously described 18S rRNA gene qPCR assay for quantifying *Plasmodium falciparum* in blood samples was evaluated. Assay performance characteristics including analytical sensitivity, reportable range, precision, accuracy and specificity were assessed using experimental data and data compiled from phase 1 volunteer infection studies conducted between 2013 and 2019. Guidelines for validation of laboratory-developed molecular assays were followed.

Results: The reportable range was 1.50 to 6.50 log₁₀ parasites/mL with a limit of detection of 2.045 log₁₀ parasites/mL of whole blood based on a parasite diluted standard series over this range. The assay was highly reproducible with minimal intra-assay (SD = 0.456 quantification cycle (C_q) units [0.137 log₁₀ parasites/mL] over 21 replicates) and inter-assay (SD = 0.604 C_q units [0.182 log₁₀ parasites/mL] over 786 qPCR runs) variability. Through an external quality assurance program, the QIMR assay was shown to generate accurate results (quantitative bias + 0.019 log₁₀ parasites/mL against nominal values). Specificity was 100% after assessing 164 parasite-free human blood samples.

Conclusions: The 18S rRNA gene qPCR assay is specific and highly reproducible and can provide reliable and accurate parasite quantification. The assay is considered fit for use in evaluating drug efficacy in malaria clinical trials.

Keywords: *Plasmodium falciparum*, Hydrolysis probe, Quantitative PCR, Validation, Volunteer infection studies, MIQE

Background

Enhanced global efforts aimed at malaria control and elimination have led to a significant decrease in the incidence of malaria over recent years [1]. However, the emergence of drug-resistant parasites [2–4] has the potential to undermine progress made to date and highlights the need for ongoing development of effective and affordable anti-malarial drugs and vaccines.

*Correspondence: claire.wang@uq.edu.au

² Child Health Research Centre, The University of Queensland, Brisbane, Australia

Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Volunteer infection studies (VIS), also known as controlled human malaria infection studies, afford a safe and reproducible model to assess anti-malarial drug efficacy at an early stage, and predict drug activity in natural infections [5–9]. They have become a standard model for early evaluation of the efficacy of candidate drugs or vaccines [7, 8, 10–12]. In VIS, participants are inoculated with sporozoites or blood stage parasites via mosquito bites or, injection [7, 8, 13]. A critical safety consideration in VIS is the parasite density in the peripheral blood of infected participants. Likewise, this metric is critical to determining the efficacy of vaccines and drugs acting against blood stage parasites. Traditionally, parasitaemia has been monitored via microscopy [14, 15]. However, microscopy has a limited sensitivity of ~20 parasites/ μ L blood in expert laboratories [16, 17] and can produce false-negative results in low-density or asymptomatic infections [18, 19].

Molecular techniques, such as quantitative PCR (qPCR) and reverse transcription qPCR (RT-qPCR), have become the preferred methodology for evaluating drug and vaccine efficacy in early phase clinical trials across many centres [7, 10, 20–22]. Notably, these methods provide robust and accurate quantification of parasitaemia with increased sensitivity compared to the traditional methods: for example, allowing the detection of parasites in blood 1 to 4 days earlier than microscopy [16, 22, 23]. These enhanced performance characteristics of qPCR also ensure the safety of VIS by reducing the risk of dangerous levels of parasitaemia and minimizing discomfort of participants [10, 24]. The increased sensitivity and dynamic range of qPCR also permits improved estimation of important parasite parameters, such as asexual parasite maturation and multiplication rate [25]; these measures enable more accurate statistical modelling to determine pharmacodynamics of new anti-malarial treatments and characterization of the minimum inhibitory concentration for dose optimization [23, 26, 27].

However, ongoing assay characterization and validation is important to ensure accurate results are reported and to support clinical trials under rigorous regulatory review. For this purpose, additional validation was performed to assess performance characteristics of a previously described 18S rRNA gene qPCR assay [28] for quantifying *Plasmodium falciparum* parasites in healthy volunteers enrolled in VIS. A different 18S rRNA qPCR assay was recently qualified for this purpose through the U.S. FDA [22]. Parameters assessed were according to published guidelines [29–32], namely analytical sensitivity, reportable range, precision, accuracy and specificity.

Methods

Plasmodium 18S rRNA gene qPCR assay

The 18S rRNA gene qPCR assay has been previously described [28]. In brief, 2 mL blood samples were collected into ethylenediaminetetraacetic acid (EDTA) tubes from malaria-naïve participants enrolled in VIS. Tubes were centrifuged for 5 min at 2500 rpm to pellet red blood cells (RBCs), packed RBCs (~250 μ L) were removed and mixed thoroughly with 250 μ L phosphate buffered saline (PBS) and subjected to DNA extraction using QIAamp DNA Blood Mini Kit (Qiagen, Australia), with a final eluate volume of 100 μ L. Five microlitres of nucleic acid were added to the qPCR mix as per the previously published qPCR assay specific for the *P. falciparum* 18S rRNA gene [29, 30] using the Qiagen Rotor-Gene platform (Qiagen, Australia) and the Qiagen QuantiTect Probe mix (Qiagen, Australia.) Details of the primers and probe are presented in Additional file 1: Table S1.

Controls and calibration verification

A reference standard for calibration was prepared from *P. falciparum* 3D7 ring-stage synchronized culture using methods previously described [28, 33]. The parasite density of the material was estimated by fluorescence-activated cell sorting to be 3.19×10^6 parasites/mL (6.50 \log_{10} parasites/mL) and this material was subjected to nucleic acid extraction. The extract was then serially diluted in uninfected human blood extracts to produce 5 tenfold dilutions ranging from 3.19×10^5 to 31.9 parasites/mL (6.50 to 1.50 \log_{10} parasites/mL). The six standards were analysed on a single qPCR run in duplicate to establish an external standard curve [34]. The linear regression model from an external standard curve (slope -3.324) was then imported into all qPCR runs with fixing of the intercept to the highest standard concentration (6.50 \log_{10} parasites/mL), a standardized calibration method. The remaining five standards were used during each subsequent qPCR and acted as positive controls, and for calibration verification by confirming adequate PCR efficiency (>90%). A single sample of each concentration occurred with each qPCR run during clinical trials. Levey–Jennings charts were used to monitor quantification cycle (C_q) fluctuations of positive samples [16, 29, 35]. Two negative controls were included in each qPCR run to monitor reagent contamination. An internal control targeting an equine herpesvirus (EHV) was used to monitor nucleic acid extraction efficiency and qPCR inhibition [28, 36]. Samples were spiked with a known concentration of the EHV prior to DNA extraction. C_q values obtained from the EHV PCR testing were considered acceptable if they fell within mean $C_q \pm 2$ standard deviations (SD) of each extraction per qPCR run [37].

Overview of 18S rRNA gene qPCR assay validation

The methodology used to validate the 18S rRNA gene qPCR assay followed the validation of laboratory-developed molecular assays for infectious diseases guidelines [29] and the minimum information for publication of quantitative real-time PCR (qRT-PCR) experiments [30]. Clinical and Laboratory Standards Institute guidelines were also used for guidance [31, 32]. The following characteristics of the 18S rRNA gene qPCR assay were assessed: analytical sensitivity, reportable range, precision including intra-assay and inter-assay variability, accuracy and specificity.

Nine standards ranging from 1.50 to 6.50 \log_{10} parasites/mL were run on 3 consecutive days with seven technical replicates and a negative control. This dataset was used to determine the analytical sensitivity, reportable range and intra-assay variability. A linear regression model was used to estimate the relationship between \log_{10} concentration of standard and C_q value. For this model technical replicates were averaged within days. The slope estimate was used to calculate qPCR efficiency. The intra-assay SD for each concentration was calculated using analysis of variance accounting for day using all technical replicate data. The overall SD is the pooled SD estimates across concentrations. Probit regression was used to estimate the limit of detection (LOD) at which 95% of the samples tested positive.

Inter-assay variability was assessed using the six standards data from 786 qPCR runs occurring during 30 VIS conducted between 2013 and 2019. The inter-assay SD for each concentration was calculated using analysis of variance accounting for study cohort. The overall SD is the pooled SD estimates across concentrations. The cohort SD for each concentration was calculated using analysis of variance accounting for study cohort and the interaction between study cohort and study. The overall cohort SD is the pooled SD estimates across concentrations. Data were checked for outliers and analysed using Stata version 14.2 (StataCorp, College Station, TX) or SPSS version 23.0 (IBM Corp., Armonk, NY). Data were summarized for each standard concentration by frequency and percentage detected, mean C_q , SD, and relative variability of C_q measured as the percent coefficient of variation (%CV).

Accuracy

To evaluate the accuracy of the 18S rRNA gene qPCR assay, the QIMR qPCR results were compared to the University of Washington reverse transcription quantitative PCR (RT-qPCR) via an external quality assurance (EQA) project [38]. This project was initiated in 2014 by the University of Washington to examine the qualitative and

quantitative agreement between centres conducting VIS. The EQA panel comprised five level dilutions and negative controls preserved in 0.5 mL of frozen whole blood ($n=60$) shipped to each laboratory on dry ice. The concentrations were originally de-identified, but later identified as high (5.48 \log_{10} parasites/mL or 300,000 parasites/mL), mid (3.78 \log_{10} parasites/mL or 6000 parasites/mL), low (2.78 \log_{10} parasites/mL or 600 parasites/mL), very low (1.78 \log_{10} parasites/mL or 60 parasites/mL), trace (0.78 \log_{10} parasites/mL or 6 parasites/mL) and a negative control. The methods and results from five VIS centres participating in this program have been published [38]. The QIMR laboratory subsequently obtained this EQA panel and tested these with the QIMR 18S rRNA gene qPCR method. Data were reported as the parasite number detected and quantitative bias against nominal values and University of Washington values using Bland–Altman plots.

In addition, to estimate the impact of genetic diversity of the 18SrRNA gene on the assay performance, a search was conducted for single nucleotide polymorphisms (SNPs) in the area where primers and probe bind in 218 *P. falciparum* genomes in PlasmoDB (version 46, released the 6th Nov 2019) from 18 different countries in Asia, South-America and Africa.

Specificity

Analytical specificity was previously determined to be 100% by comparing the sequence of the nucleic acid target to sequences available on publicly accessible databases using the NCBI BLAST search tool [37]. Here, an updated BLAST search was conducted to confirm specificity; briefly, primers and probe sequences were submitted using the nBLAST tool to check the assay's specificity to *P. falciparum* and cross-matched against other *Plasmodium* species (including *Plasmodium ovale*, *Plasmodium malariae*, *Plasmodium knowlesi* and *Plasmodium vivax*) and human genomic DNA on 7th April 2020. Diagnostic specificity was evaluated by analysing qPCR assay on blood samples collected from malaria-naïve participants ($n=164$) enrolled in 30 cohorts of induced blood stage malaria VIS during 2013 to 2019. Samples were collected from participants prior to being inoculated with blood-stage parasites.

Potential qPCR-interfering substances were considered, including endogenous substances such as haem, leukocyte DNA and plasma proteins in plasma [39, 40], and exogenous substances such as EDTA anticoagulant [39, 41]. The QIMR standard extraction protocol included the following procedures to avoid some known inhibitory substances: pelleting RBCs to remove plasma and buffy coat containing plasma proteins and leukocytes [28]. The nucleic acid extraction kit used was suitable for removing

known inhibitory chemicals such as citrate, heparin and EDTA (QIAmp DNA Blood Mini Kit). An interference study was performed to examine the potential effect of haem (from haemoglobin) and EDTA from collection tubes on qPCR inhibition. Blood was collected in EDTA-coated tubes from healthy participants and subjected to centrifugation at 2500 rpm for 5 min. Plasma and buffy coat were removed and aliquots ($n=20$) of 250 μL pelleted RBCs were mixed with 250 μL PBS and spiked with known concentration of *P. falciparum* culture and internal control EHV. A parallel extraction using 500 μL PBS ($n=20$) with the same positive and EHV spikes was performed simultaneously. All extracts were analysed using 18S rRNA gene qPCR and EHV qPCR assays. C_q values from both assays were analysed using Student's *t*-test to evaluate the effect of potential interference substances on the assay.

Ethical approvals

Blood samples were collected during the course of VIS, which were all approved by the QIMR Human Research Ethics Committee. Details of the studies and ethical approval have been published ([42], Additional file 1: Table S2).

Results

The overall performance characteristics of the 18S rRNA gene qPCR assay are summarized in Table 1. Details of each characteristic are given in the following section and in Additional file 1: Tables S1–S4.

Analytical sensitivity

The lowest concentration that could reliably be detected by the qPCR assay in $\geq 95\%$ positive samples ($\text{LOD}_{95\%}$) as determined by Probit regression was 2.045 \log_{10} parasites/mL (95% CI 1.875–2.591) or 111 parasites/mL (95%

CI 75–390) of whole blood. The upper limit of quantification for the 18S rRNA gene qPCR assay (i.e., the highest standard of the reportable range [43] which was restricted to the highest concentration available in the laboratory) was 6.50 \log_{10} parasites/mL. The lower limit of quantification (LLoQ; i.e., the lowest standard concentration that can be quantitatively determined with acceptable precision [43]) was 1.50 \log_{10} parasites/mL of whole blood.

Reportable range

A summary of C_q values for each standard dilution is presented in Additional file 1: Table S3. Two C_q values were identified as being outliers and changed to not-detected (ND); 2.20 \log_{10} parasites/mL [$C_q=38.24$] and 1.80 \log_{10} parasites/mL [$C_q=42.98$] as they were visually aberrant being greater than the mean C_q of the standard concentration below and close to the maximum value of its range. Parasites were not detected in an additional four replicates at 1.80 \log_{10} parasites/mL and nine replicates at 1.50 \log_{10} parasites/mL. Linear regression was used to estimate the relationship between \log_{10} concentration and C_q value with intercept of 43.370 (95% CI 43.097, 43.643), slope of -3.353 (95% CI -3.425 , -3.281), mean squared error of 0.088 and correlation coefficient (R^2) of 0.997. There was no evidence of non-linear behaviour in the residual plot (Additional file 1: Figs. S1 and S2). The qPCR efficiency was 99%. The reliable reportable range of the 18S rRNA gene qPCR assay was 1.50 to 6.50 \log_{10} parasites/mL.

Precision

Intra-assay variability

Variability between replicates pooled across days increased as the standard concentration decreased, but the %CV remained low (i.e. $<3\%$) (Additional file 1:

Table 1. 18S rRNA gene qPCR performance characteristics

Analytical sensitivity	
Limit of detection (LOD)	2.045 \log_{10} parasites/mL of whole blood
Lower limit of quantification (LLoQ)	1.50 \log_{10} parasites/mL of whole blood
Upper limit of quantification (ULoQ)	6.50 \log_{10} parasites/mL of whole blood
Reportable range	1.50 to 6.50 \log_{10} parasites/mL of whole blood
Precision	
Intra-assay variability	Overall standard deviation (SD) = 0.456 C_q units (0.137 \log_{10} parasites/mL)
Inter-assay variability	Overall standard deviation (SD) = 0.604 C_q units (0.182 \log_{10} parasites/mL)
Accuracy	
EQA program	Bias: + 0.019 \log_{10} parasites/mL against nominal parasitaemia values [38]
Specificity	
Analytical specificity	100%
Diagnostic specificity	100%

Table S3). The overall SD was 0.456 C_q units (0.137 \log_{10} parasites/mL) pooled across all concentrations, and the overall %CV was less than 3% (1.45%). All negative controls were ND.

Inter-assay variability

The SD between studies increased as standard concentration decreased; however, variability was low ($CV < 3\%$) and stable across concentrations (Additional file 1: Table S4). The overall SD between studies was 0.604 C_q units (0.182 \log_{10} parasites/mL) pooled across all qPCR. The Overall SD between cohorts was 1.71 C_q units, reflecting that environmental and temporal variability was much higher than both intra-assay and inter-assay SD but remained stable across concentrations.

Accuracy

The QIMR 18S rRNA gene qPCR assay detected 7/9 samples at the very low (1.78 \log_{10} parasites/mL) level and 2/11 samples at the trace (0.78 \log_{10} parasites/mL) level (Fig. 1). There were no false positives among the 10 blinded malaria-negative samples. The QIMR assay quantitatively aligned with both nominal values and with host laboratory RT-qPCR-generated parasitaemia (Additional file 1: Fig. S3). Quantitative bias for the QIMR 18S rRNA gene qPCR assay was minimal: +0.019 \log_{10} parasites/

mL against the nominal values and +0.104 \log_{10} parasites/mL against the UW RT-qPCR.

The QIMR assay binds to three of the five 18S rRNA gene copies present in *P. falciparum* 3D7 strain located in chromosome 1, 11 and 13. Using the PlasmoDB platform, 20 SNPs scattered throughout these three chromosomes were identified. None of the SNPs were present in the binding regions or either the primers or probe.

Specificity


BLAST searching (conducted on 7th April 2020) confirmed the 18S rRNA gene qPCR assay primer and probe sequences are specific to the *P. falciparum* 18S rRNA gene and do not cross-react with human genomic DNA or other *Plasmodium* species, including *P. ovale*, *P. malariae*, *P. vivax* and *P. knowlesi*. Likewise, the 18S rRNA gene qPCR assay provided negative results for all duplicates of blood samples from all 164 malaria-naïve VIS participants prior to inoculation. Thus, the analytical and diagnostic specificity were both determined to be 100%.

The effects of haemoglobin and EDTA as potential PCR inhibitory substances were examined. The differences between the means of parallel spiked blood and PBS extracts were compared. C_q values from both 18S and EHV qPCR obtained from two sample types were not significantly different (18S mean C_q difference = -0.136, $p=0.14$; EHV mean C_q difference = 0.134, $p=0.064$). Therefore, there was no significant influence on the assay attributed to the presence of haemoglobin and EDTA.

Discussion

Estimates of parasitaemia in malaria-naïve participants represent key data in VIS [15, 44]. This study reports the high sensitivity, reproducibility, and accuracy of a qPCR method to detect *P. falciparum* in blood samples. The clinical trial dataset used to assess parasitaemia included 786 assay runs across 30 clinical trials. This 18S rRNA gene qPCR assay was shown to have excellent analytic sensitivity and accuracy compared to the nominal value in the EQA study [38]. The ability to quantify low level parasitaemia allows for a greater increase in the safety of participants and for more accurate assessment of early recrudescence.

The LOD reported in this study is more precise than the LOD reported by Rockett et al. [28] (2.045 \log_{10} parasites/mL versus 1.806 \log_{10} parasites/mL). This is a consequence of the use of a larger number of replicates of the standard material over a wider range of dilutions [45] and the 95th percentile of the probit curve is used here whereas the 50th percentile of the lowest standard concentration was used in the earlier study. It is worth noting that LLoQ, the lowest standard concentration,



was reported in this study instead of LoQ and that the LLoQ had a value lower than the LOD. VIS studies are unique in that the volunteers are tested and confirmed malaria negative upon enrolment and the positivity of blood samples is due to inoculation of the volunteer with malaria parasites. Any positive results, regardless of the quantification value, is of clinical significance and ensures volunteer safety in VIS studies. Although LOD is an important measure of diagnostic accuracy, it is less relevant in the context of VIS studies and the reportable range, specified by LLoQ and ULoQ, is most relevant for this application. C_q values that translate to positive findings lower than the LLoQ ($1.5 \log_{10}$ parasites/mL) have been observed in QIMR studies, particularly at the time when parasites first emerge in peripheral blood and during the “tail phase” after anti-malarial treatments. Detection and quantification below the defined reportable range remains plausible due to stochastic sampling, but high levels of variability should be expected due to the increase in stochastic effect on sampling and amplification at low target concentrations [22, 46]. By triplicate qPCR testing in clinical trials, this variation at low concentrations can be quantified. Approaches to further increase sensitivity include increasing sample volume input [47] or RT-qPCR measuring the more abundant 18S rRNA transcripts [48].

The 18S rRNA gene qPCR assay described here was designed and validated for the quantification of specific strains of *P. falciparum* (including NF54/3D7). The protocol and methodology were designed specifically for the purpose of this VIS setting. Using the current assay to quantify parasitaemia in field-collected samples may present separate challenges, such as ensuring sample integrity and the presence of circulating gametocytes. Ballard et al. [49] have previously shown the QIMR assay to give equivalent parasitaemia estimates to those from microscopy in field samples.

Assay validation is key to ensuring comparable accuracy among research centres. Individual standard protocols were used by each of the five participating centres in the EQA study [38] and QIMR results were comparable at higher concentrations and with higher sensitivity at lower concentrations. The QIMR assay presented consistently low intra-assay variability and inter-assay variability and was specific to the target, all of which are essential ingredients to VIS.

The main disadvantage of qPCR assays in a long-running clinical trial program is the need for a standard curve, because of variation between controls and the need for constant generation of new biological material. An alternative is droplet digital PCR (ddPCR). ddPCR allows direct quantification without the need for a

standard curve. However, this approach is costly and not widely available [50].

Although multiple qPCR and RT-qPCR assays have been reported in the context of quantitating *P. falciparum* parasitaemia, the processes involved in the pre-analytical and analytical steps will affect the final outcome. Thus, because of its rigorous validation, this study represents a robust DNA-based method for quantifying malaria parasites with the overarching aim to contribute to a future standardized guideline for quantification of malaria parasites in a variety of settings.

Conclusion

This study describes a comprehensive validation on a real-time qPCR assay using a hydrolysis probe for quantification of *P. falciparum* parasites in clinical trials. The assay was found to be highly sensitive and specific and able to produce reliable and reproducible results in agreement with international laboratories, thereby providing accurate estimation of parasite load for parasite growth and clearance rate before, during and after anti-malarial treatment. The assay is considered fit for purpose as an analytically validated qPCR assay to be used in malarial clinical trials.

Abbreviations

%CV: Coefficient of variation; ddPCR: Droplet digital PCR; EDTA: Ethylenediaminetetraacetic acid; EHV: Equine herpesvirus; EQA: External quality assurance; LOD: Limit of detection; LoQ: Limit of quantification; MIQE: Minimum information for publication of quantitative real-time PCR experiments; PBS: Phosphate buffered saline; qPCR: Quantitative polymerase chain reaction; qRT-PCR: Quantitative real-time PCR; RBC: Red blood cell; rRNA: Ribosomal RNA; RT-qPCR: Reverse transcription qPCR; SD: Standard deviation; VIS: Volunteer infection studies.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12936-021-03717-y>.

Additional file 1: Table S1. Oligonucleotide sequences used in this study. **Table S2.** List of VIS included in validation. **Table S3.** Summary of C_q values of each standard of 7 technical replicates over 3 consecutive days. **Table S4.** Summary of inter-assay variability for standards data for 18S rRNA gene qPCR assays. **Figure S1.** Scatter plot of C_q value for each \log_{10} concentration of calibrator. **Figure S2.** Residual plot for the linear regression of \log_{10} concentration of calibrator predicting C_q . **Figure S3.** Bland–Altman plots comparing: (A) QIMR qPCR versus nominal, (B) QIMR qPCR versus UW RT-qPCR.

Acknowledgements

We thank the clinical studies team at Q-Pharm Pty Ltd and all study participants; J. Wilson for manuscript preparation; the Queensland Paediatric Infectious Diseases Laboratory (QPID) for PCR analyses; Medicines for Malaria Venture.

Authors' contributions

Study conceptions and design: CYW, EB, PO, JSM. Design, implementation and validation of qPCR assays: CYW, DW, JG. Statistical analysis and interpretation:

EB, PO, LM. Manuscript writing: CYW, EB, PO, DW, ZP. All authors read and approved the final manuscript.

Funding

This study was supported by funds from the Bill & Melinda Gates Foundation received via Medicines for Malaria Venture (OPP111147). JSM was supported by an NHMRC Practitioner Fellowship (APP1135955) and NHMRC Program Grant (1132975).

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on request.

Declarations

Ethics approval and consent to participate

Blood samples were collected during the course of VIS, which were all approved by the QIMR Human Research Ethics Committee. Details of the studies and ethical approval have been published ([42], Additional file 1: Table S2).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Centre for Children's Health Research, Children's Health Queensland, Brisbane, Australia. ² Child Health Research Centre, The University of Queensland, Brisbane, Australia. ³ QIMR Berghofer Medical Research Institute, Brisbane, Australia. ⁴ Departments of Laboratory Medicine and Microbiology, University of Washington, Seattle, WA, USA. ⁵ Center for Emerging and Re-Emerging Infectious Diseases, University of Washington, Seattle, WA, USA. ⁶ UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia. ⁷ School of Medicine, The University of Queensland, Brisbane, Australia.

Received: 14 April 2020 Accepted: 29 March 2021

Published online: 10 April 2021

References

- WHO. World malaria report 2019. Geneva: World Health Organization; 2019.
- Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperazine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis*. 2016;16:357–65.
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2014;371:411–23.
- Ranson H, Lissenden N. Insecticide resistance in African *Anopheles* mosquitoes: a worsening situation that needs urgent action to maintain malaria control. *Trends Parasitol*. 2016;32:187–96.
- McCarthy JS, Ruckle T, Elliott SL, Ballard E, Collins KA, Marquart L, et al. A single-dose combination study with the experimental antimalarials Artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage *Plasmodium falciparum* in healthy volunteers. *Antimicrob Agents Chemother*. 2019;64:e01371-e1419.
- Collins KA, Wang CY, Adams M, Mitchell H, Robinson GJ, Rampton M, et al. A *Plasmodium vivax* experimental human infection model for evaluating the efficacy of interventions. *J Clin Invest*. 2020;130:2920–7.
- Kamau E, Alemayehu S, Feghali KC, Komisar J, Regules J, Cowden J, et al. Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research. *Malar J*. 2014;13:288.
- Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. *Nat Rev Immunol*. 2011;11:57–64.
- Llanos-Cuentas A, Casapia M, Chuquiyaquiri R, Hinojosa JC, Kerr N, Rosario M, et al. Antimalarial activity of single-dose DSM265, a novel *Plasmodium* dihydroartemisinin dehydrogenase inhibitor, in patients with uncomplicated *Plasmodium falciparum* or *Plasmodium vivax* malaria infection: a proof-of-concept, open-label, phase 2a study. *Lancet Infect Dis*. 2018;18:874–83.
- Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, et al. Diagnosis and treatment based on quantitative PCR after controlled human malaria infection. *Malar J*. 2016;15:398.
- Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, et al. Safety and comparability of controlled human *Plasmodium falciparum* infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge. *PLoS ONE*. 2014;9:e109654.
- Andrews KA, Wesche D, McCarthy J, Mohrle JJ, Tarning J, Phillips L, et al. Model-informed drug development for malaria therapeutics. *Annu Rev Pharmacol Toxicol*. 2018;58:567–82.
- Mordmüller B, Supan C, Sim KL, Gomez-Perez GP, Ospina Salazar CL, Held J, et al. Direct venous inoculation of *Plasmodium falciparum* sporozoites for controlled human malaria infection: a dose-finding trial in two centres. *Malar J*. 2015;14:117.
- Tangpukdee N, Duangdee C, Wilairatana P, Krudsood S. Malaria diagnosis: a brief review. *Korean J Parasitol*. 2009;47:93–102.
- Roestenberg M, Mordmüller B, Ockenhouse C, Mo A, Yazdanbakhsh M, Krensner PG. The frontline of controlled human malaria infections: a report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016. *Vaccine*. 2017;35:7065–9.
- Murphy SC, Shott JP, Parikh S, Etter P, Prescott WR, Stewart VA. Malaria diagnostics in clinical trials. *Am J Trop Med Hyg*. 2013;89:824–39.
- Murphy SC, Prentice JL, Williamson K, Wallis CK, Fang FC, Fried M, et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage *Plasmodium falciparum* infections in malaria human challenge trials. *Am J Trop Med Hyg*. 2012;86:383–94.
- Coleman RE, Sattabongkot J, Promstaporn S, Maneechai N, Tippayachai B, Kengluetcha A, et al. Comparison of PCR and microscopy for the detection of asymptomatic malaria in a *Plasmodium falciparum/vivax* endemic area in Thailand. *Malar J*. 2006;5:121.
- Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. *Nat Rev Microbiol*. 2014;12:833–40.
- Collins KA, Wang CY, Adams M, Mitchell H, Rampton M, Elliott S, et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. *J Clin Invest*. 2018;128:1551–62.
- Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, et al. A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic *Plasmodium falciparum* infection during controlled human malaria infection by mosquito bites and direct venous inoculation. *J Infect Dis*. 2018;217:693–702.
- Sellie AM, Chang M, Hanron AE, Billman ZP, Stone BC, Zhou K, et al. Beyond blood smears: qualification of *Plasmodium* 18S rRNA as a biomarker for controlled human malaria infections. *Am J Trop Med Hyg*. 2019;100:1466–76.
- Marquart L, Baker M, O'Rourke P, McCarthy JS. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. *Antimicrob Agents Chemother*. 2015;59:4249–59.
- McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, et al. A pilot randomised trial of induced blood-stage *Plasmodium falciparum* infections in healthy volunteers for testing efficacy of new antimalarial drugs. *PLoS ONE*. 2011;6:e21914.
- Hermesen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. *Am J Trop Med Hyg*. 2004;71:196–201.
- White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. *Antimicrob Agents Chemother*. 2013;57:5792–807.
- Hien TT, White NJ, Thuy-Nhien NT, Hoa NT, Thuan PD, Tarning J, et al. Estimation of the in vivo MIC of Cipargamin in uncomplicated *Plasmodium falciparum* malaria. *Antimicrob Agents Chemother*. 2017;61:e01940-e2016.

28. Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Whiley DM, Nissen MD, et al. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of *Plasmodium falciparum* load in experimentally infected human volunteers. *Malar J*. 2011;10:48.
29. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. *Clin Microbiol Rev*. 2010;23:550–76.
30. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem*. 2009;55:611–22.
31. CLSI. Protocols for determination for limits of detection and limits of quantitation. Approved guideline. Wayne, PA; 2004. Contract No. EP17-A.
32. CLSI. Defining, establishing and verifying reference intervals in the clinical laboratory. Approved guideline. Wayne, PA; 2008. Contract No. C28-A3.
33. Dixon MW, Peatey CL, Gardiner DL, Trenholme KR. A green fluorescent protein-based assay for determining gametocyte production in *Plasmodium falciparum*. *Mol Biochem Parasitol*. 2009;163:123–6.
34. Forlenza M, Kaiser T, Savelkoul HF, Wiegertjes GF. The use of real-time quantitative PCR for the analysis of cytokine mRNA levels. *Methods Mol Biol*. 2012;820:7–23.
35. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. *Clin Chem*. 1981;27:493–501.
36. Bialasiewicz S, Whiley DM, Buhner-Skinner M, Bautista C, Barker K, Aitken S, et al. A novel gel-based method for self-collection and ambient temperature postal transport of urine for PCR detection of *Chlamydia trachomatis*. *Sex Transm Infect*. 2009;85:102–5.
37. Wang CYT, McCarthy JS, Stone WJ, Bousema T, Collins KA, Bialasiewicz S. Assessing *Plasmodium falciparum* transmission in mosquito-feeding assays using quantitative PCR. *Malar J*. 2018;17:249.
38. Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, et al. External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance. *PLoS ONE*. 2014;9:e97398.
39. Schrader C, Schielke A, Ellerbroek L, John R. PCR inhibitors—occurrence, properties and removal. *J Appl Microbiol*. 2012;113:1014–26.
40. Al-Soud WA, Radstrom P. Purification and characterization of PCR-inhibitory components in blood cells. *J Clin Microbiol*. 2001;39:485–93.
41. Wilson IG. Inhibition and facilitation of nucleic acid amplification. *Appl Environ Microbiol*. 1997;63:3741–51.
42. Wockner LF, Hoffmann I, Webb L, Mordmuller B, Murphy SC, Kublin JG, et al. Growth Rate of *Plasmodium falciparum*: analysis of parasite growth data from malaria volunteer infection studies. *J Infect Dis*. 2020;221:963–72.
43. Forootan A, Sjoback R, Bjorkman J, Sjogreen B, Linz L, Kubista M. Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR). *Biomol Detect Quantif*. 2017;12:1–6.
44. McCarthy JS, Baker M, O'Rourke P, Marquart L, Griffin P, Hoof van Huijsduijnen R, et al. Efficacy of OZ439 (artefenomel) against early *Plasmodium falciparum* blood-stage malaria infection in healthy volunteers. *J Antimicrob Chemother*. 2016;71:2620–7.
45. Tadesse FG, Lanke K, Nebie I, Schildkraut JA, Goncalves BP, Tiono AB, et al. Molecular markers for sensitive detection of *Plasmodium falciparum* asexual stage parasites and their application in a malaria clinical trial. *Am J Trop Med Hyg*. 2017;97:188–98.
46. Budowle B, Eisenberg AJ, van Daal A. Validity of low copy number typing and applications to forensic science. *Croat Med J*. 2009;50:207–17.
47. Imwong M, Hanchana S, Malleret B, Renia L, Day NP, Dondorp A, et al. High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. *J Clin Microbiol*. 2014;52:3303–9.
48. Adams M, Joshi SN, Mbambo G, Mu AZ, Roemmich SM, Shrestha B, et al. An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density *Plasmodium falciparum* and *Plasmodium vivax* infections in small volume blood samples. *Malar J*. 2015;14:520.
49. Ballard E, Wang CYT, Hien TT, Tong NT, Marquart L, Pava Z, et al. A validation study of microscopy versus quantitative PCR for measuring *Plasmodium falciparum* parasitemia. *Trop Med Health*. 2019;47:49.
50. Koepfli C, Nguitragool W, Hofmann NE, Robinson LJ, Ome-Kaius M, Sat-tabongkot J, et al. Sensitive and accurate quantification of human malaria parasites using droplet digital PCR (ddPCR). *Sci Rep*. 2016;6:39183.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

